Cardinal Health Inc

These names were recently added to the Morningstar Wide Moat Focus Index.

It continues to inflict pain on drug manufacturers and distributors.

We review the changes to the Morningstar Wide Moat Focus Index during the latest reconstitution and reveal the least-expensive names.

Plus, the 10 cheapest names in the index today.

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended April 12.

All three companies still trade at 4 stars, however.

These low- and medium-uncertainty stocks are trading at the largest discounts to our fair value estimates.

More than 50 stocks derive their wide moats from just one source. Is that a problem?

Here are some defensive investments to consider in this volatile market.

Its core operations will be needed no matter how market dynamics shift.

These high-quality stocks are cheap on a host of metrics.

The pharma distributor has a solid foundation and a bright outlook, in our opinion.

Though the market is slightly overvalued, our analysts are finding pockets of opportunity.

Innovation, clearing regulatory picture, corporate restructurings, and capital redeployment should continue for healthcare stocks in the fourth quarter.

These 10 undervalued Morningstar US Dividend Growth Index constituents are cash-rich businesses with sustainable and growing payouts.

The Morningstar US Dividend and Buyback Index focuses on companies that are shareholder-friendly capital allocators.

The Morningstar Wide Moat Focus Index made room for some undervalued consumer defensive stocks in June.

We believe companies with moats from switching costs and intangible assets are less vulnerable.

Disastrous quarter aside, the wide-moat firm remains in a strong long-term position within the U.S. pharmaceutical market.

Investors are underappreciating the moaty nature of the healthcare supply chain and the formidable competitive advantages that have insulated these firms.